Evidence map›Paper›PMID 40382585›Full record

ArticleHuman genomics2025

Exploring potential methylation markers for ovarian cancer from cervical scraping samples.

Ju-Yin Lien, Lu Ann Hii, Po-Hsuan Su, Lin-Yu Chen, Kuo-Chang Wen, Hung-Cheng Lai, Yu-Chao Wang

Abstract read
In one paragraph

Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ju-Yin LienInstitute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Lu Ann HiiInstitute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Po-Hsuan SuCollege of Health Technology, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
Lin-Yu ChenDepartment of Obstetrics and Gynecology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Kuo-Chang WenDepartment of Obstetrics and Gynecology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Hung-Cheng LaiDepartment of Obstetrics and Gynecology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. hclai30656@gmail.com.
Yu-Chao WangInstitute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan. yuchao@nycu.edu.tw.

Funding

National Science and Technology Council NSTC 112-2221-E-A49-088-MY3
6 · The paper itself

Abstract

backgroundOvarian cancer has the highest mortality rate among gynecological cancers, making early detection crucial, as the five-year survival rate drops from 92% with early-stage diagnosis compared to 31% with late-stage diagnosis. Current diagnostic methods such as histopathological examination and detection of cancer antigen 125 and human epididymis protein 4 biomarkers are either invasive or lack specificity and sensitivity. However, the Papanicolaou (Pap) test, which is widely used for cervical cancer screening, shows the potential for detecting ovarian cancer by identifying tumor DNA in cervical scrapings. Since aberrant DNA methylation patterns are linked to cancer progression, DNA methylation offers a promising avenue for early diagnosis. Therefore, this study aimed to develop a methylation-based machine-learning model to stratify patients with ovarian cancer from the cervical scraping samples collected via Pap test.

resultsCervical scrapings were collected by gynecologists using conventional Pap smears. In total, 160 samples were collected: 95 normal, 37 benign, and 28 malignant. Methylation data were generated using the Illumina Infinium MethylationEPIC BeadChip array, which contains approximately 850,000 CpG loci. Methylation data were initially divided into training and testing sets in a 3:1 ratio comprising 120 and 40 samples, respectively. A two-step methylation-based model was trained using the training data for classification: a principal component analysis (PCA) model, consisting of 30 features, to classify samples as normal or tumor; then a gradient boosting model, containing 16 features, to further stratify tumor samples as benign or malignant. The two-step model achieved an accuracy of 0.88 and an F1-score of 0.86 on the testing data. Furthermore, an over-representation analysis was conducted to explore the functions associated with genes mapped from differentially methylated positions (DMPs) in comparisons between normal and tumor samples, as well as between benign and malignant samples. These results suggest that DMPs may be associated with olfactory transduction when comparing normal versus tumor samples, and immune regulation when comparing benign and malignant samples.

conclusionsOur two-step model shows promise for predicting ovarian cancer and suggests that cervical scrapings may be a viable alternative for sample collection during screening.

Indexed as

Biomarkers, TumorDNA MethylationOvarian NeoplasmsAdultAgedCervix UteriCpG IslandsEarly Detection of CancerFemaleHumansMachine LearningMiddle AgedPapanicolaou TestUterine Cervical NeoplasmsVaginal SmearsBiomarkers, TumorBiomarkerCancer screeningEpigeneticsMachine learningMethylationOvarian cancerPapanicolaou test (Pap test)

Identifiers

PMID40382585
PMCPMC12085859

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.